Across the recent three months, 12 analysts have shared their insights on Acadia Healthcare Co ACHC, expressing a variety of opinions spanning from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 3 | 5 | 4 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 1 | 2 | 2 | 0 | 0 |
| 2M Ago | 0 | 0 | 0 | 0 | 0 |
| 3M Ago | 1 | 3 | 2 | 0 | 0 |
Insights from analysts' 12-month price targets are revealed, presenting an average target of $89.33, a high estimate of $102.00, and a low estimate of $70.00. Highlighting a 2.37% decrease, the current average has fallen from the previous average price target of $91.50.
Investigating Analyst Ratings: An Elaborate Study
A comprehensive examination of how financial experts perceive Acadia Healthcare Co is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Gary Taylor | TD Cowen | Lowers | Buy | $91.00 | $101.00 |
| Andrew Mok | Barclays | Lowers | Overweight | $89.00 | $91.00 |
| Ann Hynes | Mizuho | Lowers | Neutral | $70.00 | $84.00 |
| Kevin Fischbeck | B of A Securities | Lowers | Buy | $90.00 | $105.00 |
| Andrew Mok | Barclays | Lowers | Overweight | $91.00 | $100.00 |
| Pito Chickering | Deutsche Bank | Maintains | Hold | $70.00 | - |
| Ann Hynes | Mizuho | Raises | Neutral | $84.00 | $77.00 |
| Andrew Mok | Barclays | Announces | Overweight | $100.00 | - |
| Sarah James | Cantor Fitzgerald | Maintains | Neutral | $90.00 | - |
| Ben Hendrix | RBC Capital | Maintains | Outperform | $94.00 | - |
| Gary Taylor | TD Cowen | Raises | Outperform | $101.00 | $86.00 |
| Andrew Mok | UBS | Raises | Buy | $102.00 | $88.00 |
Key Insights:
- Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Acadia Healthcare Co. This offers insight into analysts' perspectives on the current state of the company.
- Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Acadia Healthcare Co compared to the broader market.
- Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Acadia Healthcare Co's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Acadia Healthcare Co's market position. Stay informed and make well-informed decisions with our Ratings Table.
Stay up to date on Acadia Healthcare Co analyst ratings.
Unveiling the Story Behind Acadia Healthcare Co
Acadia Healthcare Co Inc acquires and develops behavioral healthcare facilities in the United States, United Kingdom, and Puerto Rico. Acute inpatient psychiatric facilities and specialty treatment facilities contribute the vast majority of Acadia's revenue in the United States. The U.S. facilities receive the major proportion of payments from Medicaid, with the second-largest proportion from commercial payors. In the United Kingdom, the majority of Acadia's revenue comes from its healthcare facilities, and virtually all of the payment received is from the National Health Service.
Breaking Down Acadia Healthcare Co's Financial Performance
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Revenue Growth: Acadia Healthcare Co's remarkable performance in 3 months is evident. As of 31 March, 2024, the company achieved an impressive revenue growth rate of 9.06%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Acadia Healthcare Co's net margin excels beyond industry benchmarks, reaching 9.95%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Acadia Healthcare Co's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 2.7%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Acadia Healthcare Co's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.4%, the company showcases efficient use of assets and strong financial health.
Debt Management: Acadia Healthcare Co's debt-to-equity ratio is below the industry average at 0.69, reflecting a lower dependency on debt financing and a more conservative financial approach.
Analyst Ratings: What Are They?
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in Benzinga Pro.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
